Tevard Biosciences, Inc., a biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, presented new preclinical data at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, held from May 11-15 in Boston. The company announced that its next-generation suppressor tRNAs (sup-tRNAs) restore full-length dystrophin protein and achieve wild-type levels of functional rescue in multiple mouse models of nonsense mutation-mediated Duchenne muscular dystrophy (DMD). Additionally, Tevard presented data showing that its novel sup-tRNAs provide durable rescue of full-length titin protein in a mouse model and functional rescue in human cardiomyocyte models of dilated cardiomyopathy caused by TTN truncations (DCM-TTNtv).
The presented programs highlight the versatility of the suppressor tRNA platform and its ability to restore native protein expression in a cell-specific, durable manner. Tevard’s compact tRNA architecture enables flexible AAV packaging, precise dose control, and broad applicability for pathogenic nonsense mutations across diverse unmet medical needs. According to the company, these data demonstrate that its sup-tRNAs can achieve approximately 100% restoration of full-length dystrophin in DMD models, a significant improvement over previous approaches that often result in partial restoration. For DCM-TTNtv, the sup-tRNAs delivered durable full-length titin rescue, addressing a critical unmet need for patients with this form of cardiomyopathy.
The findings were detailed in a press release distributed by Reportable, Inc. Tevard is advancing programs in muscular dystrophies, heart disease, and neurological disorders. For more information about the company and its platform, visit www.tevard.com. The full announcement, including downloadable images and bios, is available here.
